ASCO 2015 Multiple Myeloma Abstracts –
Oral Presentations
Oral presentations related to multiple myeloma will take place on two days during the 2015 American Society of Clinical Oncology (ASCO) annual meeting. There will be one oral presentation on Monday, June 1, as part of a session on chimeric antigen receptor T-cell (CAR-T) therapy for cancer. All the remaining myeloma-related oral presentations will be during a session on Tuesday, June 2.
The list below contains the titles and authors of all multiple myeloma oral presentations at ASCO 2015. Each entry in the list also includes a link to the full text of the relevant abstract at the ASCO website.
Links to PDF files containing presentation slides will be added to entries in this list as those files are made available to The Beacon courtesy of the ASCO presenters.
Please note that this list does not include summary / review presentations that take place during some sessions, nor does it include education session presentations.
The Beacon also has similar lists of ASCO 2015 multiple myeloma-related poster presentations, e-abstracts, and education session presentations as well as news articles about multiple myeloma at the ASCO 2015 meeting.
| Session | Chimeric Antigen Receptor T-Cell Therapy for B-Cell Malignancies |
| Type | Clinical Science Symposium |
| Time | Monday June 1, 3:00 PM to 4:30 PM |
| Location | E Arie Crown Theater |
8517 - Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma
Alfred L. Garfall, Marcela Valderrama Maus, Simon F. Lacey, Yolanda D. Mahnke, Jan J. Melenhorst, Zhaohui Zheng, Dan T. Vogl, Adam D. Cohen, Brendan M. Weiss, Karen Dengel, Naseem D.S. Kerr, Wei-Ting Hwang, Bruce Levine, Carl H. June, Edward Allen Stadtmauer (abstract, related Beacon news article)
| Session | Myeloma |
| Type | Oral Abstract Session |
| Time | Tuesday June 2, 9:45 AM to 12:45 PM |
| Location | E354b |
8508 - ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Sagar Lonial, Meletios A. Dimopoulos, Antonio Palumbo, Darrell White, Sebastian Grosicki, Ivan Spicka, Adam Walter-Croneck, Philippe Moreau, María-Victoria Mateos, Hila Magen-Nativ, Andrew Belch, Donna Ellen Reece, Meral Beksac, Masafumi Taniwaki, Christoph Röllig, Anil K. Singhal, Jessica Katz, Eric W. Bleickardt, Valerie Poulart, Paul G. Richardson, ELOQUENT-2 Investigators (abstract, presentation slides [PDF] courtesy of Dr. Lonial, and related journal article)
8509 - Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR
Meletios A. Dimopoulos, Philippe Moreau, Antonio Palumbo, Douglas E Joshua, Ludek Pour, Roman Hajek, Thierry Facon, Heinz Ludwig, Albert Oriol, Hartmut Goldschmidt, Laura Rosinol, Jan Straub, Aleksandr Suvorov, Carla Araujo, Tomas Pika, Gianluca Gaidano, Katja Weisel, Vesselina Goranova-Marinova, Heidi H. Gillenwater, Wee Joo Chng (abstract)
Progress in the Therapy of Relapsed and Refractory Multiple Myeloma - The Contribution of Big Data
Jeffrey Lee Wolf (no abstract)
8510 - Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM)
Todd M. Zimmerman, Kent A. Griffith, Jagoda Jasielec, Cara Ann Rosenbaum, Kathryn McDonnell, Jessica Waite-Marin, Jesus G. Berdeja, Noopur S. Raje, Donna Ellen Reece, Ravi Vij, Mattina Alonge, Shaun Rosebeck, Sandeep Gurbuxani, Malek Faham, Katherine A Kong, Joan Levy, Andrzej J. Jakubowiak (abstract, presentation slides [PDF] courtesy of Dr. Zimmerman)
8511 - Results from two phase III studies of bortezomib (BTZ) consolidation vs observation (OBS) post-transplant in patients (pts) with newly diagnosed multiple myeloma (NDMM)
Christian Straka, Martin Vogel, Jürgen Müller, Martin Kropff, Bernd Metzner, Christian Langer, Herbert Sayer, Wolfram Jung, Heinz Albert Dürk, Hannes Wandt, Florian Bassermann, Martin Gramatzki, Wolf Rösler, Stefan Knop, Hans-Heinrich Wolf, Wolfram Brugger, Monika Martha Engelhardt, Thomas Fischer, Hermann Einsele (abstract)
Optimal Management of Newly Diagnosed Transplant-Eligible Multiple Myeloma
Saad Zafar Usmani (no abstract, presentation slides [PDF] courtesy of Dr. Usmani)
LBA8512 - Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius)
Sagar Lonial, Brendan M. Weiss, Saad Zafar Usmani, Seema Singhal, Ajai Chari, Nizar J. Bahlis, Andrew Belch, Amrita Y. Krishnan, Robert A. Vescio, María-Victoria Mateos, Amitabha Mazumder, Robert Z. Orlowski, Heather J Sutherland, Joan Blade, Emma Catherine Scott, Huaibao Feng, Imran Khan, Clarissa M. Uhlar, Tahamtan Ahmadi, Peter Michael Voorhees (abstract, presentation slides [PDF] courtesy of Dr. Lonial, and related Beacon news article)
8513 - A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM)
Jesus G. Berdeja, Tara K. Gregory, Jeffrey Matous, Lowell L. Hart, Rami Owera, Joseph Ronald Mace, James H. Essell, Ian Flinn, Edward Anthony Faber (abstract, presentation slides [PDF] courtesy of Dr. Berdeja)
New Drug Classes in Plasma Cell Disorders
Suzanne Lentzsch (no abstract)
